Diabetic peripheral neuropathy (DPN) is the most common complication in both type 1 and type 2 diabetes. Here we studied some phenotypic features of a well-established animal model of type 2 diabetes, the leptin receptor-deficient db − /db − mouse, and also the effect of long-term (6 mo) treatment with coenzyme Q10 (CoQ10), an endogenous antioxidant. Diabetic mice at 8 mo of age exhibited loss of sensation, hypoalgesia (an increase in mechanical threshold), and decreases in mechanical hyperalgesia, cold allodynia, and sciatic nerve conduction velocity. All these changes were virtually completely absent after the 6-mo, daily CoQ10 treatment in db − /db − mice when started at 7 wk of age. There was a 33% neuronal loss in the lumbar 5 dorsal root ganglia (DRGs) of the db − /db − mouse versus controls at 8 mo of age, which was significantly attenuated by CoQ10. There was no difference in neuron number in 5/6-wk-old mice between diabetic and control mice. We observed a strong down-regulation of phospholipase C (PLC) β3 in the DRGs of diabetic mice at 8 mo of age, a key molecule in pain signaling, and this effect was also blocked by the 6-mo CoQ10 treatment. Many of the phenotypic, neurochemical regulations encountered in lumbar DRGs in standard models of peripheral nerve injury were not observed in diabetic mice at 8 mo of age. These results suggest that reactive oxygen species and reduced PLCβ3 expression may contribute to the sensory deficits in the late-stage diabetic db − /db − mouse, and that early long-term administration of the antioxidant CoQ10 may represent a promising therapeutic strategy for type 2 diabetes neuropathy.is a debilitating complication of both type 1 and type 2 diabetes, affecting up to 50% of diabetes patients (1-5). DPN can be observed early in human diabetes (6, 7). Early neurophysiological studies indicated that at initial stages of the illness, the severity of the polyneuropathy was similar in type 1 and type 2 diabetes patients (8). However, more recent studies showed distinct differences both in humans and rodent models. Thus, progressive axonal atrophy and loss are more serious in type 1 diabetes, which in contrast to type 2 shows nodal and paranodal degenerative changes, as well as more severe downstream effects on neuroskeletal and adhesive proteins (9).In type 1 and type 2 diabetes, many patients initially experience painful diabetic neuropathy, allodynia, which subsides and then is replaced by loss of sensation, hypoalgesia (5, 10, 11). A similar course of disease has been noted in the db
/db− mouse, just one of many animal models of diabetes (SI Text), has since then been extensively studied as a particularly robust model for type 2 DPN (14).Previous studies of mammalian DPN models have reported a decrease in impulse conduction velocity (CV) in several peripheral nerves, interpreted as being caused by a reduction in number of large or medium-sized axons (15-20), demyelination (18,19,(21)(22)(23), or axon shrinkage/atrophy (24, 25). Unmyelinated and myelinated fibers in the skin a...